TAYLOR, SYLLA & AGIN, LLP

View full entity profile (contributions, contracts, SEC) →

Lobbying Income

—

Filings

Unique Clients

Active Period

2013–2014

Lobbying Income by Year

Registrant-reported income from clients on LDA filings

Year	Lobbying Income	Filings	Clients
2014	—	3	1
2013	—	3	1

Top Clients

Largest clients by registrant-reported income

Client	Reported Income	Filings	Period
FIGHT TO LIVE	—	6	2013–2014

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
No government targets were reported in these filings.

Top Issues Lobbied

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	2
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	1

Bills Explicitly Cited (1)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 2090113th Congress

Patient Choice Act of 2013

2013 · third_quarter · Client: FIGHT TO LIVE

Open original LDA filing ↗

Cited source text and reported amounts

The Patient Choice Act - HR 2090 To obtain provisional approval of drugs in clinical trials for patients with terminal and life threatening illnesses. This legislation would allow individuals to obtain drugs outside of the scope of Phase I and Phase II clinical trials.

Client expense: — · Firm income: —

Matched citations: HR 2090

Source: Senate LDA

TAYLOR, SYLLA & AGIN, LLP — Lobbying Disclosure | Poliscope